Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc., through subsidiary Amneal Pharmaceuticals LLC, entered into Amendment No. 3 to its Term Loan Credit Agreement, converting on a cashless basis existing term loans into new term loans with an aggregate principal amount of $2.039 billion and incurring an additional $45.2 million term loan used to prepay at par remaining existing loans.
The amendment reduces the interest rate margin on these Amendment No. 3 Term Loans by 50 basis points to 1.50% for base rate loans and 2.50% for loans based on the secured overnight financing rate, while keeping the stated maturity at August 1, 2032. It also permits a future repricing transaction without a prepayment premium if it occurs after February 3, 2027. The company estimates annualized cash interest expense savings of approximately $12 million compared with the prior credit agreement, based on amounts outstanding immediately before the amendment.
Amneal Pharmaceuticals, Inc. reported that stockholders at a July 31, 2026 special meeting approved the Transaction Proposal to enter into the Membership Interest Purchase Agreement and acquire 100% of the issued and outstanding membership interests of Kashiv BioSciences, LLC. Disinterested stockholders cast 138,265,079 votes for, 655,759 against and 67,147 abstaining, satisfying the required approval condition.
Stockholders also approved the Stock Issuance Proposal to issue 28,942,108 shares of Class A common stock to the Kashiv sellers for Nasdaq Listing Rule 5635(a)(2) compliance, with 286,714,072 votes for, 1,791,016 against and 62,071 abstentions. Of 319,331,346 shares outstanding on the June 25, 2026 record date, 288,567,159 were represented, constituting a quorum. Closing of the Kashiv transaction is expected in the second half of 2026, assuming all remaining conditions and required regulatory approvals are satisfied.
Amneal Pharmaceuticals reported Q2 2026 net revenue of $796 million, up 10% from $725 million a year earlier. Net income attributable to Amneal was $58 million, with diluted EPS of $0.18. Adjusted EBITDA was $206 million and adjusted diluted EPS $0.30, both higher than Q2 2025.
Specialty net revenue grew 17%, Affordable Medicines rose 13%, while AvKARE declined 4%. For the first half of 2026, net cash (used in) provided by operating activities was $(47,987) thousand versus $91,227 thousand provided in the prior-year period.
The company repriced its $2.084 billion Term Loan B, cutting the rate by 50 bps to SOFR plus 250 bps, expected to save about $12 million in annual cash interest, and plans an additional $350 million Term Loan B to help fund the pending Kashiv BioSciences acquisition. 2026 guidance was raised: net revenue to $3.10–$3.20 billion, adjusted EBITDA to $750–$780 million, and adjusted diluted EPS to $0.96–$1.06. Net debt was $2.66 billion with non-GAAP net leverage of 3.6x for the last twelve months ended June 30, 2026.
Amneal Pharmaceuticals is asking stockholders to approve its acquisition of 100% of Kashiv BioSciences’ membership interests pursuant to a Membership Interest Purchase Agreement. At closing Amneal will pay $375,000,000 in cash and issue 28,942,108 shares of Class A common stock to the sellers. The sellers may receive up to $350,000,000 in contingent cash payments tied to U.S. regulatory milestones and potential royalty payments equal to 25% of annual aggregate gross profits above specified hurdles for up to 12 years. The transaction is conditioned on stockholder approvals (the transaction proposal and the stock issuance proposal), HSR Act clearance, certain Indian regulatory approvals and other closing conditions. The Independent Committee and the Amneal Board each unanimously recommend a vote FOR all proposals.
The special meeting will be held online on July 31, 2026. The record date for voting was June 25, 2026, and Amneal had 319,331,346 shares outstanding as of that date. Completion of the Transaction requires both the transaction approval (by Amneal disinterested stockholders) and the stock issuance approval; either failure will prevent closing.
Amneal Pharmaceuticals is seeking shareholder approval to acquire 100% of Kashiv BioSciences under a Membership Interest Purchase Agreement dated April 21, 2026. Consideration at closing includes $375,000,000 in cash and 28,942,108 shares of Amneal Class A common stock, with up to $350,000,000 of contingent cash and potential royalty payments equal to 25% of certain excess gross profits for up to 12 years. The Board and the Independent (Conflicts) Committee unanimously recommend voting FOR (transaction approval, stock issuance and an adjournment proposal). The transaction is conditioned on disinterested stockholder approval, Nasdaq shareholder approval for the share issuance, HSR clearance and certain Indian regulatory approvals, and is expected to close in the second half of 2026.
Amneal Pharmaceuticals director Deborah M. Autor reported an open-market sale of Class A Common Stock. On May 11, 2026, she sold 34,819 shares at a weighted average price of $12.94 per share in multiple trades between $12.75 and $13.27. Following the sale, she directly holds 93,660 shares.
Amneal Pharmaceuticals director J. Kevin Buchi reported routine equity compensation moves. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common shares at no cash cost, bringing his direct holdings to 75,077 shares.
On May 6, 2026, he also received a new grant of 19,824 restricted stock units, each representing a contingent right to one Class A share. A separate trust associated with him holds 262,072 Class A shares indirectly. The filing shows no open-market stock purchases or sales.
Amneal Pharmaceuticals director Deborah M. Autor increased her equity stake through equity compensation activity. On May 7, 2026, 34,819 restricted stock units were converted into 34,819 shares of Class A Common Stock, reflecting an exercise of derivative securities. Following this settlement, she directly held 128,479 Class A shares. On May 6, 2026, she was also credited with 19,824 new restricted stock units, each representing a contingent right to receive one share of Class A Common Stock, adding to her unvested equity awards.
Amneal Pharmaceuticals director Jeffrey P. George reported routine equity compensation activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares and bringing his direct holdings to 344,614 shares.
These 34,819 restricted stock units were previously granted and each unit represented a right to receive one share of Class A Common Stock upon vesting. On May 6, 2026, he was also awarded 19,824 new restricted stock units, which will convert into Class A shares when they vest under the company’s standard vesting schedule tied to the annual meeting and one‑year anniversary of grant.